The Immunoglobulins Market was valued at US$ 16.3 billion in 2022 and is expected to expand at a CAGR of 6.2% from 2023 to 2031, reaching approximately US$ 27.7 billion by the end of the forecast period. Immunoglobulins, or antibodies, play a crucial role in treating immune deficiencies, autoimmune disorders, and infectious diseases, driving consistent demand in the healthcare industry.

Get Sample PDF Brochure from here: www.transparencymarketresearch.com/sample/…p_id=52353   

Rising Demand for Intravenous and Subcutaneous Immunoglobulin Therapies

The demand for intravenous immunoglobulin (IVIG) and subcutaneous immunoglobulin (SCIG) therapies is growing due to their effectiveness in treating a wide range of immune-related conditions. IVIG remains the dominant segment, but SCIG is gaining popularity due to its convenience, reduced side effects, and self-administration capabilities.

Key Market Drivers

• Increasing Prevalence of Immunodeficiency Disorders: Rising cases of primary and secondary immunodeficiency disorders are propelling the demand for immunoglobulin therapies.
• Growing Geriatric Population: As the elderly population is more prone to immune-related conditions, the demand for immunoglobulin-based treatments is steadily increasing.
• Advancements in Plasma-Derived Therapies: Technological advancements in plasma fractionation and purification processes are enhancing the efficacy and safety of immunoglobulin therapies.
• Expanding Applications in Neurology: Immunoglobulins are increasingly being used in the treatment of neurological conditions such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and multiple sclerosis.

Competitive Landscape

Major players in the immunoglobulins market are focusing on product innovation, strategic collaborations, and capacity expansion to cater to the rising demand. Key companies include:

• Shire
• CSL Behring
• Kedrion Biopharma Inc.
• Grifols, S.A.
• Octapharma
• China Biologic Products Holdings, Inc.
• Biotest AG
• Sanquin
• LFB SA

Market Segmentation

• Application
  • Neurology
  • Immunology
  • Hematology
  • Others
• Route of Administration
  • Intravenous
  • Subcutaneous
  • Intramuscular
• End-user
  • Hospitals
  • Clinics
  • Homecare

By Region

• North America leads the market due to strong healthcare infrastructure, high plasma collection rates, and increasing prevalence of immune disorders.
• Europe follows closely, supported by favorable government policies and increased awareness regarding immunoglobulin therapies.
• Asia-Pacific is projected to witness the fastest growth, driven by expanding healthcare access, growing awareness, and rising investments in plasma-derived therapies.

Contact Us:

Transparency Market Research Inc.
CORPORATE HEADQUARTER DOWNTOWN,
1000 N. West Street,
Suite 1200, Wilmington, Delaware 19801 USA
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453